Chemed (NYSE: CHE) reported earnings on July 18. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), Chemed missed estimates on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew slightly. Non-GAAP earnings per share expanded. GAAP earnings per share dropped significantly.

Gross margins grew, operating margins dropped, net margins dropped.

Revenue details
 Chemed reported revenue of $357.2 million. The four analysts polled by S&P Capital IQ hoped for a top line of $368.1 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $1.44. The five earnings estimates compiled by S&P Capital IQ predicted $1.33 per share. Non-GAAP EPS of $1.44 for Q2 were 14% higher than the prior-year quarter's $1.26 per share. GAAP EPS of $0.77 for Q2 were 30% lower than the prior-year quarter's $1.10 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 28.5%, 120 basis points better than the prior-year quarter. Operating margin was 7.2%, 400 basis points worse than the prior-year quarter. Net margin was 4.1%, 190 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $369.5 million. On the bottom line, the average EPS estimate is $1.37.

Next year's average estimate for revenue is $1.49 billion. The average EPS estimate is $5.66.

Investor sentiment
 The stock has a one-star rating (out of five) at Motley Fool CAPS, with 102 members out of 141 rating the stock outperform, and 39 members rating it underperform. Among 55 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 36 give Chemed a green thumbs-up, and 19 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Chemed is outperform, with an average price target of $77.50.

Is Chemed the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.